TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19043384

Group type: EXPERIMENTAL
Intervention: Partial occlusion of the abdominal aorta by the NeuroFlo device
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional management of stroke patients
Number of subjects: 97
Study: 16464718

Group type: EXPERIMENTAL
Intervention: MIBI scintigraphy in CHF patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: MIBI scintigraphy in healthy volunteers
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of WR of MIBI with brain natriuretic peptide levels
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of WR of MIBI with left ventricular ejection fraction
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of WR of MIBI with WR of MIBG
Number of subjects: 27
Study: 12649051

Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 304

Group type: COMPARATOR
Intervention: Self‐test group
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study: 11450504

Group type: EXPERIMENTAL
Intervention: 160 mg gliclazide (study 1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 160 mg gliclazide after 2 months of therapy (80 mg t.i.d.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (study 2)
Number of subjects: 7
Study: 9240867

Group type: EXPERIMENTAL
Intervention: Zidovudine administration to mothers during prenatal and intrapartum periods, and to neonates for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8159486

Group type: EXPERIMENTAL
Intervention: TempaDOT
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: FirstTEMP
Number of subjects: 172

Group type: COMPARATOR
Intervention: Glass mercury thermometer
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Temperature measurement sites
Number of subjects: 172
Study: 3286041

Group type: COMPARATOR
Intervention: Diltiazem 30 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nifedipine 10 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Diltiazem 30 mg plus Nifedipine 10 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg with Diltiazem
Number of subjects: 11
Study: 31957648

Group type: EXPERIMENTAL
Intervention: ERRT‐M
Number of subjects: 40

Group type: COMPARATOR
Intervention: MCC
Number of subjects: 40
Study: 29615136

Group type: EXPERIMENTAL
Intervention: Dialogue-based psychosocial intervention (eight individual sessions of supported dialogues in their homes during the first six months following an acute stroke)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Dialogue-based psychosocial intervention
Number of subjects: 330
Study: 27159310

Group type: EXPERIMENTAL
Intervention: Pulley exercises initiated 6 weeks postoperatively
Number of subjects: 53

Group type: COMPARATOR
Intervention: Alternative rehabilitation program without pulleys
Number of subjects: 53
Study: 25604640

Group type: EXPERIMENTAL
Intervention: Nutrihand
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tap & Track
Number of subjects: 19

Group type: COMPARATOR
Intervention: GRAND (dietitian analysis)
Number of subjects: 19
Study: 25245439

Group type: EXPERIMENTAL
Intervention: Tamibarotene
Number of subjects: 269

Group type: COMPARATOR
Intervention: ATRA
Number of subjects: 269
Study: 23094271

Group type: EXPERIMENTAL
Intervention: Theobromine 100 mg/l for 5 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Theobromine 200 mg/l for 5 min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no theobromine treatment)
Number of subjects: 24
Study: 20012076

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18831888

Group type: EXPERIMENTAL
Intervention: Crossover from enflurane to desflurane anaesthesia (group X)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Enflurane anaesthesia (group E)
Number of subjects: 46
Study: 15947769

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 44
Study: 11874389

Group type: EXPERIMENTAL
Intervention: 7.5 mg meloxicam once
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen three times daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac SR once
Number of subjects: 24
Study: 10495460

Group type: EXPERIMENTAL
Intervention: Immediate zidovudine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred zidovudine treatment
Number of subjects: 0
Study: 8930782

Group type: EXPERIMENTAL
Intervention: Befloxatone 5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Befloxatone 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Befloxatone 20 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Amitriptyline 50 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1327933

Group type: EXPERIMENTAL
Intervention: Whole-grain rye bread (200-300 g/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal omnivorous diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-fiber wheat bread (200-300 g/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whole-meal wheat bread (200-300 g/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whole-grain rye bread
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control period (normal diet)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-fiber wheat bread
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whole-meal wheat bread
Number of subjects: 12
Study: 3886305

Group type: EXPERIMENTAL
Intervention: 4 mg alizapride/kg body weight
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.6 mg domperidone/kg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall assessment by investigator
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 44
Study: 30753650

Group type: COMPARATOR
Intervention: Acoustic enhancement of slow-wave activity (SWA) via 50 ms sounds phase-locked to slow-waves, with 5 s ON/5 s OFF stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acoustic enhancement of slow-wave activity (SWA)
Number of subjects: 0
Study: 29419665

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) during decubitus position with limbs raised
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control protocol (decubitus position with limbs raised without NMES)
Number of subjects: 31
Study: 26839992

Group type: EXPERIMENTAL
Intervention: MIS Lateral Interbody Fusion (XLIF)
Number of subjects: 55

Group type: COMPARATOR
Intervention: MIS Transforaminal Interbody Fusion (MIS TLIF)
Number of subjects: 55
Study: 25354689

Group type: EXPERIMENTAL
Intervention: PRASE intervention (Patient Reporting and Action for a Safe Environment) which includes a 44-item questionnaire and a proforma for reporting safety incidents and positive experiences.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PRASE intervention
Number of subjects: 32
Study: 22954674

Group type: EXPERIMENTAL
Intervention: Rice containing 6.51 g resistant starch daily
Number of subjects: 90
Study: 20082714

Group type: EXPERIMENTAL
Intervention: exercise therapy + usual care
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) + usual care
Number of subjects: 81

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 81
Study: 19060577

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT) for 5 minutes on 3 consecutive days.
Number of subjects: 20

Group type: COMPARATOR
Intervention: No Therapeutic Touch (NTT) for 5 minutes on 3 consecutive days.
Number of subjects: 20
Study: 15821691

Group type: EXPERIMENTAL
Intervention: Conventional Twin-block (TB) appliance
Number of subjects: 70

Group type: COMPARATOR
Intervention: Modified Twin-block (MB) appliance
Number of subjects: 70
Study: 12232494

Group type: EXPERIMENTAL
Intervention: Fasting (250 kcal; 3 l fluid intake/day) without mineral supplements (n = 103)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Fasting (250 kcal; 3 l fluid intake/day) with mineral supplements (3 x 2 to 3 x 3 Bullrich's Vital) (n = 106)
Number of subjects: 209
Study: 10421283

Group type: EXPERIMENTAL
Intervention: Furosemide withdrawal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuation of furosemide therapy
Number of subjects: 20
Study: 7569764

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1288904

Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 2 mg.kg‐1 (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ranitidine liquid 2 mg.kg‐1 (Group D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo liquid (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo liquid (Group C)
Number of subjects: 80
Study: 3908214

Group type: EXPERIMENTAL
Intervention: Changing-scheme (adriamycin/cisplatinum–vincristine/cyclophosphamide–high dose methotrexate)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Adriamycin/cyclophosphamide
Number of subjects: 164

Group type: COMPARATOR
Intervention: Adriamycin/cisplatinum
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Changing-scheme
Number of subjects: 164
Study: 31683779

Group type: EXPERIMENTAL
Intervention: P4 (dairy and vegetable protein blend)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Casein
Number of subjects: 14

Group type: COMPARATOR
Intervention: Whey
Number of subjects: 14

Group type: COMPARATOR
Intervention: Soy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pea
Number of subjects: 14
Study: 27785534

Group type: EXPERIMENTAL
Intervention: Patient-specific pre-contoured plate (case group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intra-operatively contoured plates (control group)
Number of subjects: 21
Study: 27131984

Group type: EXPERIMENTAL
Intervention: Two short implants
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Three short implants
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Four short implants
Number of subjects: 23

Group type: COMPARATOR
Intervention: Comparison among groups
Number of subjects: 23
Study: 25316331

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 450

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 450
Study: 22381164

Group type: EXPERIMENTAL
Intervention: Statin therapy in SES stratum (2,735 patients)
Number of subjects: 10221

Group type: COMPARATOR
Intervention: Non-statin therapy in SES stratum (2,294 patients)
Number of subjects: 10221

Group type: EXPERIMENTAL
Intervention: Statin therapy in BMS stratum (2,576 patients)
Number of subjects: 10221

Group type: COMPARATOR
Intervention: Non-statin therapy in BMS stratum (2,616 patients)
Number of subjects: 10221
Study: 21268411

Group type: EXPERIMENTAL
Intervention: Well-Being Therapy (WBT)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Anxiety Management (AM)
Number of subjects: 162
Study: 17879527

Group type: EXPERIMENTAL
Intervention: Chinese drugs combined with benazepril
Number of subjects: 108

Group type: COMPARATOR
Intervention: Benazepril alone (Control)
Number of subjects: 108
Study: 16219435

Group type: EXPERIMENTAL
Intervention: Menthol penetration-enhanced tetracaine gel (4% tetracaine in carbomer vehicle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-penetration-enhanced tetracaine gel (4% tetracaine in carbomer vehicle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12114420

Group type: EXPERIMENTAL
Intervention: NSC 655649 single-dose format (step 1)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NSC 655649 multiple-dose format (step 2)
Number of subjects: 69
Study: 10051803

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (360 mg Mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 11
Study: 7595698

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX) with cranial radiation (CRT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional-dose methotrexate (CD-MTX)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All patients (regardless of treatment)
Number of subjects: 66
Study: 2405136

Group type: EXPERIMENTAL
Intervention: 1,25‐dihydroxyvitamin D3
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: dihydrotachysterol
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control period measurements
Number of subjects: 82
Study: 419460

Group type: EXPERIMENTAL
Intervention: Debrisan (dextranomer)
Number of subjects: 50
Study: 31742898

Group type: EXPERIMENTAL
Intervention: 5 mg dapagliflozin
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin
Number of subjects: 151
Study: 31195337

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teriflunomide 7 mg
Number of subjects: 0
Study: 27132630

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine care (control group, n = 30)
Number of subjects: 90
Study: 25838191

Group type: EXPERIMENTAL
Intervention: Risk-reduction rationale flyer
Number of subjects: 300

Group type: COMPARATOR
Intervention: No-education control
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Flyer versions 1-4 (different emphasis frames)
Number of subjects: 300
Study: 22907764

Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (IIT) - basal-bolus glulisine + glargine administrations
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard care (SC) - glargine administration + oral antidiabetic drugs
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (IIT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: rs753482AC+CC (eNOS polymorphism)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Baseline CD34(+)KDR(+) in rs753482AA
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Highest circulating CD34(+)KDR(+) in IIT rs753482AA
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lowest circulating CD34(+)KDR(+) in SC rs753482AC+CC
Number of subjects: 46
Study: 21821303

Group type: EXPERIMENTAL
Intervention: Gefitinib 250mg/day
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Gefitinib 500mg/day
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 19674382

Group type: EXPERIMENTAL
Intervention: Algorithm-guided treatment (AGT)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 210
Study: 17325332

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 42902
Study: 15809789

Group type: EXPERIMENTAL
Intervention: Direct Trocar Insertion (DTI)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Veress Needle (VN)
Number of subjects: 598
Study: 11282170

Group type: EXPERIMENTAL
Intervention: Acute MS
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Stable MS
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: OIND patients (HIV-1-associated dementia)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: OIND patients (encephalitis)
Number of subjects: 103

Group type: COMPARATOR
Intervention: 6-methylprednisolone therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: IFN-beta1a therapy
Number of subjects: 103
Study: 9041233

Group type: EXPERIMENTAL
Intervention: MK-591 100 mg taken twice daily
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: MK-591 50 mg taken twice daily
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: MK-591 12.5 mg taken twice daily
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 7696378

Group type: EXPERIMENTAL
Intervention: 40 mg (R,S)‐propranolol.HCl
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 mg (S)‐propranolol.HCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (S)‐propranolol (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (R)‐propranolol (40 mg)
Number of subjects: 0
Study: 3653122

Group type: EXPERIMENTAL
Intervention: Diltiazem (25 mg i.v. single dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31797417

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of aerobic and resistance exercise
Number of subjects: 160

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 160
Study: 28274169

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 10 mg/kg once a day for the first three days of life plus moderate hypothermia
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hypothermia alone
Number of subjects: 44
Study: 29027817

Group type: EXPERIMENTAL
Intervention: 600,000 IU of vitamin D3 (Cholecalciferol) over 10 days in a dose of 60,000 IU/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26327495

Group type: EXPERIMENTAL
Intervention: 100% commercial pomegranate juice
Number of subjects: 64

Group type: COMPARATOR
Intervention: apple juice (control)
Number of subjects: 64
Study: 23690366

Group type: EXPERIMENTAL
Intervention: Annexin A5 anticoagulant activity
Number of subjects: 183

Group type: COMPARATOR
Intervention: Pediatric controls
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Children with SLE and positive anti-DI antibodies
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Anti-DI antibodies
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant (LA)
Number of subjects: 183
Study: 20723551

Group type: EXPERIMENTAL
Intervention: Sleep restriction (4h time in bed per night for 5 nights)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (10h time in bed per night throughout the study)
Number of subjects: 74
Study: 18755067

Group type: EXPERIMENTAL
Intervention: Cross arch fulcrum
Number of subjects: 32

Group type: COMPARATOR
Intervention: Opposite fulcrum
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard intraoral fulcrum
Number of subjects: 32

Group type: COMPARATOR
Intervention: Basic extraoral fulcrum
Number of subjects: 32

Group type: COMPARATOR
Intervention: Finger on finger fulcrum
Number of subjects: 32

Group type: COMPARATOR
Intervention: Opposite arch fulcrum
Number of subjects: 32
Study: 15930485

Group type: EXPERIMENTAL
Intervention: 1.52 g/day DHA from capsules containing DHA-rich algal triglycerides
Number of subjects: 57

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 57
Study: 14521638

Group type: EXPERIMENTAL
Intervention: Guideline education and individual feedback
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 11077720

Group type: EXPERIMENTAL
Intervention: Preconceptional education and good metabolic control (group A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Not applicable (group B)
Number of subjects: 61
Study: 8853760

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms b.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1635487

Group type: EXPERIMENTAL
Intervention: Antenatal care provided by registered midwives
Number of subjects: 89

Group type: COMPARATOR
Intervention: Antenatal care provided by obstetricians
Number of subjects: 89
Study: 6367578

Group type: EXPERIMENTAL
Intervention: Probucol and colestipol combination
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Probucol alone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Colestipol alone
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Probucol alone or in combination
Number of subjects: 47
Study: 31484551

Group type: EXPERIMENTAL
Intervention: Rasch model of continuous variables with standardized residual analyses
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Rasch model of continuous variables
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Online dashboard for monitoring possible deductions
Number of subjects: 194
Study: 29432383

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccination at ≤7 days, 10 and 14 weeks
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccination at 10, 14 and 26 weeks
Number of subjects: 480

Group type: COMPARATOR
Intervention: RTS,S/AS01E vaccination
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (without RTS,S/AS01E)
Number of subjects: 480
Study: 26512928

Group type: EXPERIMENTAL
Intervention: Robot gait training (five sessions a week for 5 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual gait training (control group)
Number of subjects: 28
Study: 24029016

Group type: EXPERIMENTAL
Intervention: 1.0‐s stimulus response (R[S])
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5‐s stimulus response (R[L])
Number of subjects: 0
Study: 22551482

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (0.375% ropivacaine 6ml/h for 48h)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Single dose femoral nerve block (30mL of 0.5% ropivacaine)
Number of subjects: 104
Study: 20660678

Group type: EXPERIMENTAL
Intervention: DRV/r 600/100 mg BID
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: RFB 300 mg QD
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: DRV/r 600/100 mg BID plus RFB 150 mg QOD
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined treatment (DRV/r + RFB)
Number of subjects: 27
Study: 17950789

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) at an off-site center
Number of subjects: 439

Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI) at a tertiary center with cardiac surgery
Number of subjects: 439
Study: 16173217

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte (CHO-E) fluid replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 0
Study: 12554113

Group type: EXPERIMENTAL
Intervention: Fluor‐Protector + Cervitec (Test group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo varnish (Placebo group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups (Test and Placebo)
Number of subjects: 102
Study: 10214002

Group type: EXPERIMENTAL
Intervention: Historical control data adjustment procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group sequential monitoring
Number of subjects: 0